Harbour BioMed stake in US drug firm Spruce shows Chinese firmsâ growing clout, analysts say
Shanghai-based Harbour BioMedâs acquisition of a stake in US-based Spruce Biosciences is the latest example of Chinaâs novel drug developers progressing from one-time licensing deals into long-lasting...